StockData

ARS Pharmaceuticals vs Verastem

SPRY and VSTM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SPRY and VSTM compare

Verastem is the larger company, worth 1.9 times as much as ARS Pharmaceuticals ($741M against $387M).

ARS Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −164% compared with −178% at Verastem.

ARS Pharmaceuticals scores higher on the StockData Score (9 against 3 for Verastem), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSPRYVSTM
Size and price
Market cap$387M$741M
Share price$3.89$8.18
Change, 1 year−56.5%−3.9%
Change, 5 years−52.7%−77.0%
Beta (5Y)1.421.37
Employees158102
StockData Score
Total score9 (better)3
Valuation score1 (better)0
Growth score2 (better)1
Performance score11
Health score5 (better)1
Dividend score00
Valuation
P/S3.2× (better)7.4×
P/B–73.3×
FCF yield−47.3%–
Growth
Revenue growth (TTM)−14.5%–
Revenue growth, 5Y average–−19.0%
Profitability
Operating margin−161% (better)−194%
Net margin−164% (better)−178%
FCF margin−150%–
Return on equity−295%–
Financial health
Interest coverage–−141.9×
Current ratio3.25 (better)1.93
Altman Z-score−3.05 (better)−7.82
Piotroski F-score24 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions91.2%109%
Held by insiders46.7%1.8%
Insider net buying, 12 months−$284K (better)−$816K
Superinvestors holding1–
Short interest, % of float35.9%22.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.